Honokiol inhibits osteoclast differentiation and function in vitro.

Area of Science:

• Biochemistry
• Pharmacology
• Cell Biology
• Orthopedics

Background:

• Osteoclasts are critical for bone remodeling, but their excessive activity leads to bone diseases.
• Receptor activator of nuclear factor-kappaB ligand (RANKL) is a key inducer of osteoclast differentiation.
• Honokiol, a neolignan from Magnolia obovata, possesses various bioactivities.

Purpose of the Study:

• To investigate the effects of honokiol on osteoclast differentiation and function.
• To elucidate the underlying molecular mechanisms of honokiol's action on osteoclasts.

Main Methods:

• Assessed tartrate-resistant acid phosphatase (TRAP) activity and multinucleated cell formation.
• Analyzed the phosphorylation of mitogen-activated protein kinases (MAPKs) including p38, ERK, and JNK.
• Measured the expression of transcription factors c-Fos and nuclear factor of activated T cells-c1 (NFATc1).
• Evaluated actin ring disruption and osteoclastic pit formation on dentin slices.

Main Results:

• Honokiol significantly inhibited RANKL-induced TRAP activity and osteoclast formation.
• Honokiol suppressed RANKL-induced phosphorylation of p38 MAPK, ERK, and JNK.
• Honokiol reduced RANKL-induced expression of c-Fos and NFATc1.
• Honokiol disrupted actin rings in mature osteoclasts and reduced pit formation without affecting cell viability.

Conclusions:

• Honokiol inhibits osteoclast differentiation by suppressing MAPK signaling pathways and key transcription factors.
• Honokiol attenuates bone resorption by disrupting the actin cytoskeleton of mature osteoclasts.
• Honokiol demonstrates potential as a therapeutic agent for bone diseases involving excessive osteoclast activity.